What is Lutetium PRRT Therapy?

Peptide Receptor Radionuclide Therapy, or lutetium PRRT, is a type of targeted radionuclide therapy used to treat some neuroendocrine tumours. It makes use of lutetium-177 (Lu-177), a radioactive compound that is bound to a peptide molecule and specifically targets receptors on the surface of neuroendocrine tumour cells.

Rare, slow-growing tumours that develop from cells in the endocrine and neurological systems are known as neuroendocrine tumours. On their cell surface, they frequently have high somatostatin receptor expression. By delivering a radioactive payload specifically to the tumour cells with lutetium PRRT, the malignant cells are destroyed with precision while causing the least amount of harm to healthy tissues.

Awesome Image


Our skilled team of medical professionals, including experienced nuclear medicine physicians, oncologists, and radiologists, are at the forefront of Lutetium PRRT Therapy. With their extensive knowledge and expertise, we ensure that our patients receive the highest quality of care.

At Nuclear Care MD, we understand that every patient's journey is unique. We take the time to conduct thorough evaluations and develop personalized treatment plans tailored to each individual's specific needs. Our goal is to optimize the effectiveness of Lutetium PRRT Therapy while prioritizing patient comfort and well-being.

Awesome Image
Awesome Image

At Nuclear Care MD

We are dedicated to improving the lives of our patients through the innovative use of Lutetium PRRT Therapy. Our commitment to excellence, personalized care, and comprehensive support sets us apart. If you or a loved one have been diagnosed with any of the aforementioned conditions, we encourage you to explore the potential benefits of Lutetium PRRT Therapy. Contact Nuclear Care MD today to schedule a consultation and take the first step towards a brighter, healthier future.